Navigation Links
Castroviejo Straight Tying Forceps

ProductsCastroviejo Straight Tying Forceps
Company Accutome, Inc.
Item Castroviejo Straight Tying Forceps
Features 
Description Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle.
Info Accutome, Inc.
Customer Service: (800) 979-2020
Web site: http://www.accutome.com

Related medicine products :

1. Castroviejo Corneal Trephine Set
2. Castroviejo Double Ended Synechia Spatula
3. Castroviejo Cyclodialysis Spatula
4. Castroviejo Double Ended Cyclodialysis Spatula
5. Castroviejo Double Ended Lacrimal Dilator
6. Castroviejo Speculum - 15 mm
7. Castroviejo Speculum - 16 mm
8. Castroviejo Fixation Forceps
9. Castroviejo Suture Forceps
10. Fine-Castroviejo Suturing Forceps
11. Castroviejo Suturing Forceps
...potent, naturally secreted estrogen and is the maj...y, estradiol is produced from testosterone [1,2], ...rom androstenedione. Estrone and estradiol are int...ounts of estradiol are produced in the testes and ...
...potent, naturally secreted estrogen and is the maj...y, estradiol is produced from testosterone [1,2], ...rom androstenedione. Estrone and estradiol are int...ounts of estradiol are produced in the testes and ...
AxSYM Troponin-I ADV is a Microparticle Enzyme Immunoassay (MEIA) for the quantitative determination of cardiac troponin-I (cTnI) in human serum or plasma on the AxSYM System. Troponin-I values are u
...potent, naturally secreted estrogen and is the maj...y, estradiol is produced from testosterone [1,2], ...rom androstenedione. Estrone and estradiol are int...ounts of estradiol are produced in the testes and ...
Medicine Products:
(Date:12/4/2008)...ratic, study finds , , THURSDAY, Dec. 4...gned to protect against cervical cancer are rare, ..., That,s the assessment of Australian researchers ... the Gardasil vaccine were given to girls in secon...il protects against four types of human papillomav...
(Date:12/4/2008)...ewswire-FirstCall/ - Haemacure Corporation (TSX:HA...mpany developing high-value, human plasma-derived ...that is has confirmed the successful operation qua...ent at its new state-of-the-art plasma fractionati...excited that we have achieved the important milest...
(Date:12/4/2008)...- Although there are many issues,facing Americans..., the War in,Iraq -- the Holiday Season is always... and friends. But this holiday season may be even ...ced the death of a loved one.,Their loss combined...h greater,sadness, emptiness and loss. , "...
(Date:12/4/2008)...rado Trails the Nation in Giving as Demand for Non...RNewswire/ -- More than half of Coloradans report ...o charitable causes during the economic downturn, ...," the first statewide philanthropy study in Color...tober 2008. With demand for services increasing, t...
Breaking Medicine News(10 mins):Health News:Cervical Cancer Vaccine Well Tolerated 2Health News:Haemacure Confirms Operation Qualification of Production Equipment and Pursues Milestone Payment from CSL 2Health News:Haemacure Confirms Operation Qualification of Production Equipment and Pursues Milestone Payment from CSL 3Health News:In-House Hospice Offers Help to Those Living With Grief During Holiday Time 2Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 2Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 3Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 4
...alth agencies with the most effective ways of stop...onal communication and proper condom use, for exam...om consideration needle-exchange and substance-abu...ble for federal funding despite evidence of their ...
...Family Restaurant at Lloydminister, has tested pos... a virus and affects the liver and causes fever, f...comfort followed by yellow jaundice a few days lat...n of this virus from the worker to patrons of the ...
...as published the findings of the first human test ...dysfunction.// The finding shows that gene therapy...rugs, since gene therapy is beneficial for months,... treatment for erectile dysfunction. Lead author...
... heart diseases were earlier considered illnesses ...number of young people affected// with these ailme...ished in the December edition of the Mayo Clinic P... of metabolic syndrome is increasing these days. ...
Other Medicine News:Health News:Best HIV-Prevention Programs Help People Build Skills 2Health News:Best HIV-Prevention Programs Help People Build Skills 3Health News:Gene Therapy May Be the Solution for Erectile Dysfunction 2Health News:Young and Obese People Heading for Heart Trouble 2
(Date:12/4/2008)..., Dec. 4 NovaRx Corporation announ...Ph.D to the position of President and Chief Operat...re than 25 years experience in drug discovery and ...armaceutical discovery and development. He also h...y companies developing pioneering new technologies...
(Date:12/3/2008)... front-line data demonstrating potential in newly ... leukemia to be featured in two oral sessions at A...fits for chronically transfused patients by signif...gans , , - New long-term data from major in...n optimal post-surgery treatment strategy, Femara ...
(Date:12/3/2008)... Dec. 3 Sangamo BioScien...mpany will provide an update on milestones,achiev...its annual Investor,and Analyst Briefing to be he...D., President of Sigma-Aldrich Corporation,s Resea...ss and expected potential of the,two companies, c...
(Date:12/3/2008)...INS, N.Y., Dec. 3 The Leukemia &am...announce the beginning of a new clinical trial of ...ifornia, San Diego (UCSD). , , LLS is co...l speed the development and approval of a novel ap... refractory and/or 17p deleted chronic lymphocytic...
Breaking Medicine Technology:NovaRx Appoints Industry Veteran as President and COO 2NovaRx Appoints Industry Veteran as President and COO 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 2Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 3Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 4Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 5Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 6The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial 2The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial 3Advance in effort to fight malaria by tricking the mosquitos sense of smell 190 1Advance in effort to fight malaria by tricking the mosquitos sense of smell 190 2Advance in effort to fight malaria by tricking the mosquitos sense of smell 190 3Wolves find happy hunting grounds in Yellowstone National Park 189 1Wolves find happy hunting grounds in Yellowstone National Park 189 2Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference 272 1Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference 272 2Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD 167 1Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD 167 2Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD 167 3Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD 167 4
...hers funded in part by the,National Institutes of ...most cases of Goltz syndrome, a rare skin disorder...he cases appear to result from a defect in the gen...eeded to make a protein,referred to by researcher...irst identified in fruit flies, was named for the,...
...20, 2007 - Today, President Bush,Signed An Executi...Research On Pluripotent Stem Cells. Scientists hav... to pursue the potential benefits,of pluripotent s...e,potential to develop into nearly all the cell ty...human life in the process. By,expanding support fo...
Other Medicine Technology:Researchers Discover Gene For Rare Skin Disorder 2Researchers Discover Gene For Rare Skin Disorder 3Fact Sheet: Advancing Stem Cell Research While Respecting Moral,Boundaries 2Fact Sheet: Advancing Stem Cell Research While Respecting Moral,Boundaries 3